A Phase 1 Randomised, Double-Blind, Placebo-Controlled, Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of Orally Administered PRN1008 in healthy adult volunteers.
Phase of Trial: Phase I
Latest Information Update: 16 Jul 2019
Price : $35 *
At a glance
- Drugs PRN 1008 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions; First in man
- Sponsors CNS Inc
- 15 Jun 2015 Results of this trial were presented at the European League Against Rheumatism Annual Congress (EULAR 2015), according to a Principia Biopharma media release.
- 15 Jun 2015 Results published in a Principia Biopharma media release.
- 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.